Fred Saad on quality of life in patients with metastatic hormone-sensitive prostate cancer

Fred Saad on quality of life in patients with metastatic hormone-sensitive prostate cancer

From The Lancet Oncology in conversation with by The Lancet Group

April 27, 2026 · 13 min · Episode 2

About this episode

Cheryl Lai interviews Professor Fred Saad about the quality of life outcomes in patients with metastatic hormone-sensitive prostate cancer from the ARANOTE trial.

Cheryl Lai, Acting Deputy Editor of The Lancet Oncology, is joined by Professor Fred Saad (Department of Surgery/Urology, University of Montreal, Montreal, QC, Canada) to discuss pain and health-related quality-of-life outcomes from the randomised phase 3 ARANOTE trial of darolutamide in metastatic hormone-sensitive prostate cancer. Hear about the findings from the study, the importance of quality of life for patients with metastatic prostate cancer, and how clinical research in metastatic hormone-sensitive prostate cancer might look in the next 5 years. Read the full article: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00014-8/fulltext

People in this episode

Host: Cheryl Lai

Guest: Professor Fred Saad

Topics covered

  • quality of life
  • metastatic prostate cancer
  • clinical research
  • pain management
  • ARANOTE trial

Keywords

  • metastatic hormone-sensitive prostate cancer
  • quality of life
  • ARANOTE trial
  • darolutamide
  • clinical research

Mentioned in this episode

Organizations: Department of Surgery/Urology, University of Montreal, The Lancet Oncology, darolutamide

Places: Montreal, QC, Canada

More episodes of The Lancet Oncology in conversation with

Explore listener stats, chart rankings, contacts and more on the The Lancet Oncology in conversation with podcast page.